Immuno-virological and Clinical Follow-up of Persons Living With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective Study

Abstract This retrospective study evaluated Bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) in 24 persons living with human immunodeficiency virus type 2 (HIV-2, PWHIV-2), 5 naive and 19 pretreated. After a median follow-up of 37.5 months, all PWHIV-2 had a plasma viral load <40 copies/mL. Median CD4 count increased significantly from 580 to 625 cells/mm3, suggesting the effectiveness of BIC/FTC/TAF to treat HIV-2 infection.